Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effectiveness of Rivastigmine and Donepezil on Cognitive Disorders
IRCT20210819052232N1Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Nov 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of rivastigmine and donepezil in cognitive disorder (CD) (2 arms), sponsored by Isfahan University of Medical Sciences. Started Nov 2021; status: completed.
02
Drugs
rivastigminedonepezil
03
Conditions
cognitive disorder (CD)
Beyond the preview
Go deeper on IRCT20210819052232N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210819052232N1.